Healthcare Press

Givinostat Shows Positive Effects in Treating Duchenne Muscular Dystrophy

  • 📰 Medscape
  • ⏱ Reading Time:
  • 5 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 22%
  • Publisher: 55%

Health News

Givinostat,Duchenne Muscular Dystrophy,EPIDYS Trial

Results from the phase 3 EPIDYS trial show that givinostat, a drug for the treatment of Duchenne muscular dystrophy (DMD), has shown positive effects in reducing decline of muscle function and strength compared to placebo. The trial's primary endpoint, the four-stair climb assessment, worsened in both the treatment and placebo groups, but the decline was significantly smaller with givinostat. These findings provide strong support for the use of givinostat in the treatment of DMD. The drug is currently awaiting approval from the US Food and Drug Administration (FDA).

Results from the phase 3 EPIDYS trial show that givinostat, a drug for the treatment of Duchenne muscular dystrophy (DMD), has shown positive effects in reducing decline of muscle function and strength compared to placebo. The trial's primary endpoint, the four-stair climb assessment, worsened in both the treatment and placebo groups, but the decline was significantly smaller with givinostat. These findings provide strong support for the use of givinostat in the treatment of DMD.

The drug is currently awaiting approval from the US Food and Drug Administration (FDA)

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Billions Spent on DMD Meds Despite Scant Proof of EfficacyOver 7 years, the US health care system spent more than $3 billion on DMD treatments eteplirsen, golodirsen, and casimersen, despite a lack of confirmatory trial data.
Source: Medscape - 🏆 386. / 55 Read more »